Wide Ranks

GSK

GSK plc

34.33

Top Statistics
Market Cap 70 B Forward PE 8.02 Revenue Growth -1.70 %
Current Ratio 0.81 Trailing PE 22.44 Earnings Growth 0.00 %
Profit Margins 8.02 % Peg Ratio Dividend Yield 4.56 %
Enterprice / EBITA 16.46 Enterprise / Revenue 4.87 Price To Sales Trailing12 Months 2.24
Profitability
Profit Margins 8.02 % Operating Margins 8.33 %
Balance Sheet
Total Cash 3 B Total Cash Per Share 0.7870 Total Debt 16 B
Total Debt To Equity 119.37 Current Ratio 0.81 Book Value Per Share 3.43
All Measures
Shares Short Previous Month Date 1 B Held Percent Institutions 0.1537 Price To Book 10.00
Regular Market Open 34.19 Max Age 86400 Regular Market Volume 2 M
Ask 34.47 Website https://www.gsk.com Fifty Two Week High 45.93
Price To Sales Trailing12 Months 2.24 Float Shares 3 B Trailing Peg Ratio 77.42 %
Recommendation Key buy Financial Currency GBP Profit Margins 8.02 %
Date Short Interest 1 B Last Dividend Date 1 B Payout Ratio 98.54 %
Trailing Eps 1.53 Enterprise To Revenue 4.87 Target High Price 58.00
Number Of Analyst Opinions 7 Gross Margins 72.39 % Operating Margins 8.33 %
Address1 980 Great West Road Last Split Date 1 B Shares Short Prior Month 16 M
Dividend Rate 1.56 Currency USD Net Income To Common 2 B
Total Cash Per Share 0.7870 Ebitda 9 B Total Debt 16 B
Day High 34.47 Fifty Two Week Low 32.83 Volume 2 M
Short Ratio 332.00 % Target Low Price 37.00 Gmt Off Set Milliseconds -18000000
First Trade Date Epoch Utc 323 M Regular Market Day High 34.47 Shares Short 23 M
Message Board Id finmb_275442 Day Low 34.19 52 Week Change -0.0461
Uuid a7130272-5c50-3936-b6ce-1eb2c57020e3 Forward Eps 4.30 Average Volume 5 M
Time Zone Full Name America/New_York Shares Outstanding 2 B Return On Assets 0.0724
Total Cash 3 B Open 34.19 Average Daily Volume10 Day 6 M
Industry Drug Manufacturers - General Forward PE 8.02 Compensation As Of Epoch Date 1 B
Implied Shares Outstanding 2 B Quick Ratio 51.60 % Revenue Growth -1.70 %
Return On Equity 0.2185 Last Split Factor 1226:1000 Sand P52 Week Change 0.3133
Ebitda Margins 29.57 % Earnings Growth 0.00 % Target Median Price 45.00
Book Value 3.43 Beta 0.3300 Regular Market Previous Close 34.02
Regular Market Day Low 34.19 City Brentford Shares Percent Shares Out 0.0115
Held Percent Insiders 0.0006 Next Fiscal Year End 1 B Industry Disp Drug Manufacturers - General
Quote Type EQUITY Long Name GSK plc Time Zone Short Name EST
Current Ratio 0.81 Ex Dividend Date 1 B Fifty Day Average 37.57
Enterprise To Ebitda 16.46 Industry Key drug-manufacturers-general Bid 34.27
Last Fiscal Year End 1 B Exchange NYQ Operating Cashflow 7 B
Is_nasdaq_100 False Zip TW8 9GS Five Year Avg Dividend Yield 483.00 %
Market Cap 70 B Trailing Annual Dividend Yield 1.79 % Average Volume10days 6 M
Trailing PE 22.44 Trailing Annual Dividend Rate 0.6100 Most Recent Quarter 1 B
Price Hint 2 Target Mean Price 45.95 Current Price 34.33
Previous Close 34.02 Total Revenue 31 B Short Percent Of Float 0.0115
Two Hundred Day Average 40.68 Ir Website http://www.gsk.com/investors.html Country United Kingdom
Last Dividend Value 0.3890 Revenue Per Share 15.38 Is_sp_500 False
Enterprise Value 152 B Free Cashflow 6 B Recommendation Mean 2.43
Debt To Equity 119.37 Address2 Middlesex Dividend Yield 4.56 %
Go to Yahoo Finance Go to Seeking Alpha 
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

It operates through two segments, Commercial Operations and Total R&D.

The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.

It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; and multi-target strategic  alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines.

The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.

GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

dom.